Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other Non-Current Assets (2019 - 2025)

C4 Therapeutics' Other Non-Current Assets history spans 7 years, with the latest figure at $3.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 6.97% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, up 6.97%, while the annual FY2025 figure was $3.7 million, 6.97% up from the prior year.
  • Other Non-Current Assets reached $3.7 million in Q4 2025 per CCCC's latest filing, up from $211000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $3.7 million in Q4 2025 to a low of $211000.0 in Q3 2025.
  • Average Other Non-Current Assets over 5 years is $2.9 million, with a median of $3.3 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: surged 156.97% in 2022, then tumbled 93.87% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $3.3 million in 2021, then changed by 0.0% to $3.3 million in 2022, then decreased by 16.96% to $2.7 million in 2023, then increased by 26.44% to $3.4 million in 2024, then grew by 6.97% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Other Non-Current Assets are $3.7 million (Q4 2025), $211000.0 (Q3 2025), and $3.4 million (Q2 2025).